iBio, Inc. Statistics
Total Valuation
iBio, Inc. has a market cap or net worth of $78.75 million. The enterprise value is $32.48 million.
Important Dates
The next estimated earnings date is Friday, February 13, 2026, after market close.
| Earnings Date | Feb 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
iBio, Inc. has 32.54 million shares outstanding. The number of shares has increased by 133.00% in one year.
| Current Share Class | 32.54M |
| Shares Outstanding | 32.54M |
| Shares Change (YoY) | +133.00% |
| Shares Change (QoQ) | +36.66% |
| Owned by Insiders (%) | 2.46% |
| Owned by Institutions (%) | 19.87% |
| Float | 23.06M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 64.17 |
| Forward PS | n/a |
| PB Ratio | 0.87 |
| P/TBV Ratio | 1.60 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 64.95 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.39, with a Debt / Equity ratio of 0.06.
| Current Ratio | 8.39 |
| Quick Ratio | 8.21 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -107.05 |
Financial Efficiency
Return on equity (ROE) is -54.50% and return on invested capital (ROIC) is -31.35%.
| Return on Equity (ROE) | -54.50% |
| Return on Assets (ROA) | -28.82% |
| Return on Invested Capital (ROIC) | -31.35% |
| Return on Capital Employed (ROCE) | -35.19% |
| Weighted Average Cost of Capital (WACC) | 10.86% |
| Revenue Per Employee | $25,000 |
| Profits Per Employee | -$1.01M |
| Employee Count | 20 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -28.82% in the last 52 weeks. The beta is 1.25, so iBio, Inc.'s price volatility has been higher than the market average.
| Beta (5Y) | 1.25 |
| 52-Week Price Change | -28.82% |
| 50-Day Moving Average | 2.00 |
| 200-Day Moving Average | 1.17 |
| Relative Strength Index (RSI) | 58.03 |
| Average Volume (20 Days) | 1,968,965 |
Short Selling Information
The latest short interest is 3.89 million, so 11.97% of the outstanding shares have been sold short.
| Short Interest | 3.89M |
| Short Previous Month | 3.80M |
| Short % of Shares Out | 11.97% |
| Short % of Float | 16.89% |
| Short Ratio (days to cover) | 1.23 |
Income Statement
In the last 12 months, iBio, Inc. had revenue of $500,000 and -$20.11 million in losses. Loss per share was -$1.52.
| Revenue | 500,000 |
| Gross Profit | 500,000 |
| Operating Income | -20.45M |
| Pretax Income | -20.11M |
| Net Income | -20.11M |
| EBITDA | -19.67M |
| EBIT | -20.45M |
| Loss Per Share | -$1.52 |
Full Income StatementBalance Sheet
The company has $49.57 million in cash and $3.29 million in debt, with a net cash position of $46.27 million or $1.42 per share.
| Cash & Cash Equivalents | 49.57M |
| Total Debt | 3.29M |
| Net Cash | 46.27M |
| Net Cash Per Share | $1.42 |
| Equity (Book Value) | 56.04M |
| Book Value Per Share | 2.77 |
| Working Capital | 44.72M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$17.25 million and capital expenditures -$48,000, giving a free cash flow of -$17.30 million.
| Operating Cash Flow | -17.25M |
| Capital Expenditures | -48,000 |
| Free Cash Flow | -17.30M |
| FCF Per Share | -$0.53 |
Full Cash Flow StatementMargins
| Gross Margin | 100.00% |
| Operating Margin | -4,089.40% |
| Pretax Margin | -4,021.60% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
iBio, Inc. does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -133.00% |
| Shareholder Yield | -133.00% |
| Earnings Yield | -25.53% |
| FCF Yield | -21.97% |
Analyst Forecast
The average price target for iBio, Inc. is $4.00, which is 65.29% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $4.00 |
| Price Target Difference | 65.29% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | -8.61% |
| EPS Growth Forecast (5Y) | -19.50% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on November 29, 2023. It was a reverse split with a ratio of 1:20.
| Last Split Date | Nov 29, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
iBio, Inc. has an Altman Z-Score of -5.95 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.95 |
| Piotroski F-Score | 3 |
